Date: 2016-09-21
Type of information: Nomination
Compound:
Company: Alder Biopharmaceuticals (USA - WA)
Therapeutic area: CNS diseases - Neurological diseases
Type agreement: nomination
Action mechanism:
Disease:
Details: • On September 21, 2016, Alder BioPharmaceuticals announced the appointment of Nancy L. Boman as senior vice president of regulatory affairs and pharmacovigilance. Dr. Boman will be responsible for developing and implementing the regulatory strategy and pharmacovigilance program of ALD403 for migraine prevention as it advances through pivotal trials and toward a planned Biologic License Application (BLA) with the FDA. Dr. Boman has 25 years of pharmaceutical industry experience focused in clinical development and regulatory affairs, including more than ten successful drug marketing application filings. She joins Alder from Cell Therapeutics Inc., where she most recently served as the senior vice president of clinical development and regulatory affairs. Dr. Boman's prior senior clinical development and regulatory affairs experience includes positions at Genentech, Amgen and QLT. She holds a bachelor's degree, a medical degree and a Ph.D. in biochemistry from the University of British Columbia in Vancouver.
Financial terms:
Latest news:
